These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 39516243

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.
    Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D.
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
    Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A.
    Oncologist; 2024 Oct 03; 29(10):859-869. PubMed ID: 39022993
    [Abstract] [Full Text] [Related]

  • 6. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR.
    Clin Cancer Res; 2019 Aug 15; 25(16):4973-4984. PubMed ID: 31142500
    [Abstract] [Full Text] [Related]

  • 7. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, Goldstein D, Burge M, Cooray P, Nagrial A, Tebbutt NC, Thomson B, Nikfarjam M, Harris M, Haydon A, Lawrence B, Tai DWM, Simons K, Lennon AM, Wolfgang CL, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.
    Ann Oncol; 2019 Sep 01; 30(9):1472-1478. PubMed ID: 31250894
    [Abstract] [Full Text] [Related]

  • 8. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Yamaguchi T, Uemura K, Murakami Y, Kondo N, Nakagawa N, Okada K, Seo S, Hiyama E, Takahashi S, Sueda T.
    Ann Surg Oncol; 2021 Jun 01; 28(6):3135-3144. PubMed ID: 33128119
    [Abstract] [Full Text] [Related]

  • 9. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R.
    J Hematol Oncol; 2019 Dec 04; 12(1):130. PubMed ID: 31801585
    [Abstract] [Full Text] [Related]

  • 10. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, Busch OR, van Delden OM, Halfwerk H, van Hooft JE, van Lienden KP, Marchegiani G, Meijer SL, van Noesel CJ, Reinten RJ, Roos E, Schokker S, Verheij J, van de Vijver MJ, Waasdorp C, Wilmink JW, Ylstra B, Besselink MG, Bijlsma MF, Dijk F, van Laarhoven HW.
    Int J Cancer; 2020 Mar 01; 146(5):1445-1456. PubMed ID: 31340061
    [Abstract] [Full Text] [Related]

  • 11. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L, Pu N, Thompson E, Miao Y, Wolfgang C, Yu J.
    Clin Cancer Res; 2021 Feb 01; 27(3):740-748. PubMed ID: 33082211
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S, Akhoundova D, Hipp J, Follo M, Klar RFU, Philipp U, Scherer F, von Bubnoff N, Duyster J, Boerries M, Wittel U, Fritsch RM.
    BMC Cancer; 2021 Jan 11; 21(1):49. PubMed ID: 33430810
    [Abstract] [Full Text] [Related]

  • 13. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA.
    Gastroenterology; 2019 Jan 11; 156(1):108-118.e4. PubMed ID: 30240661
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T, Mizuma M, Motoi F, Ohtsuka H, Nakagawa K, Morikawa T, Unno M.
    J Hepatobiliary Pancreat Sci; 2023 Jun 11; 30(6):815-824. PubMed ID: 36408698
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T.
    PLoS One; 2019 Jun 11; 14(12):e0227366. PubMed ID: 31891652
    [Abstract] [Full Text] [Related]

  • 16. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS, Rhee TM, Pietrasz D, Bachet JB, Laurent-Puig P, Kong SY, Takai E, Yachida S, Shibata T, Lee JW, Park HC, Zang DY, Jeon K, Lee J, Kim M, Kim HS, Kang HJ, Lee YK.
    Sci Rep; 2019 Nov 18; 9(1):16971. PubMed ID: 31740696
    [Abstract] [Full Text] [Related]

  • 17. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial.
    Pinson J, Henriques J, Beaussire L, Sarafan-Vasseur N, Sa Cunha A, Bachet JB, Vernerey D, Di Fiore F, Schwarz L, PANACHE01-PRODIGE48 group.
    Ann Surg; 2024 Nov 01; 280(5):734-744. PubMed ID: 39101207
    [Abstract] [Full Text] [Related]

  • 18. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
    Macgregor-Das A, Yu J, Tamura K, Abe T, Suenaga M, Shindo K, Borges M, Koi C, Kohi S, Sadakari Y, Dal Molin M, Almario JA, Ford M, Chuidian M, Burkhart R, He J, Hruban RH, Eshleman JR, Klein AP, Wolfgang CL, Canto MI, Goggins M.
    J Mol Diagn; 2020 Jun 01; 22(6):748-756. PubMed ID: 32205290
    [Abstract] [Full Text] [Related]

  • 19. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M, Alnaggar M, Liang S, Chen J, Xu K, Dong S, Du D, Niu L.
    Cell Physiol Biochem; 2018 Jun 01; 47(4):1556-1564. PubMed ID: 29940591
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer.
    Hálková T, Bunganič B, Traboulsi E, Minárik M, Zavoral M, Benešová L.
    Genes (Basel); 2024 Oct 07; 15(10):. PubMed ID: 39457426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.